Desvenlafaxine succinate (DVS) results in a sustained reduction in number of moderate-to-severe hot flushes (HFs)

Abstract

ObjectiveDVS, a nonhormonal therapy, has been shown in clinical trials to significantly reduce the frequency and severity of moderate-to-severe hot flushes in postmenopausal women. The objective of this analysis was to compare the long-term effect of DVS with placebo in treating menopausal HFs.DesignThis was a 52-week, multicenter, randomized, double-blind, placebo-controlled trial.Materials and methodsTableReduction of number of moderate and severe HFs, observed dataAdjusted Mean Change from Baseline (SE)WeekDVS 100 mgPlaceboP-value vs. placebo4−6.92 (0.34)−5.31 (0.44)0.00312−7.80 (0.36)−6.04 (0.49)0.00313–16−7.69 (0.34)−5.70 (0.45)<0.00117–20−7.70 (0.36)−5.56 (0.49)<0.00121–24−7.76 (0.37)−5.53 (0.50)<0.00125–28−8.01 (0.35)−6.29 (0.47)0.00329–32−8.20 (0.35)−6.59 (0.49)0.00733–36−8.00 (0.35)−6.61 (0.47)0.01537–40−8.12 (0.36)−6.79 (0.49)0.02141–44−8.36 (0.35)−6.69 (0.47)0.00345–48−8.39 (0.36)−6.85 (0.48)0.00749–52−8.26 (0.37)−6.93 (0.49)0.024 Open table in a new tab ResultsThe frequency of moderate-to-severe HFs was significantly reduced from baseline with DVS 100 mg at all time points up to week 52 (all comparisons P<0.001). The decreases in number of moderate-to-severe hot flushes with DVS were significantly greater than those observed in the placebo group at all time points up to week 52 (all comparisons P<0.05; Table).ConclusionsIn this analysis, the significant decrease from baseline seen with DVS 100 mg was maintained and was significantly better than placebo for the full 52-week duration of the trial. ObjectiveDVS, a nonhormonal therapy, has been shown in clinical trials to significantly reduce the frequency and severity of moderate-to-severe hot flushes in postmenopausal women. The objective of this analysis was to compare the long-term effect of DVS with placebo in treating menopausal HFs. DVS, a nonhormonal therapy, has been shown in clinical trials to significantly reduce the frequency and severity of moderate-to-severe hot flushes in postmenopausal women. The objective of this analysis was to compare the long-term effect of DVS with placebo in treating menopausal HFs. DesignThis was a 52-week, multicenter, randomized, double-blind, placebo-controlled trial. This was a 52-week, multicenter, randomized, double-blind, placebo-controlled trial. Materials and methodsTableReduction of number of moderate and severe HFs, observed dataAdjusted Mean Change from Baseline (SE)WeekDVS 100 mgPlaceboP-value vs. placebo4−6.92 (0.34)−5.31 (0.44)0.00312−7.80 (0.36)−6.04 (0.49)0.00313–16−7.69 (0.34)−5.70 (0.45)<0.00117–20−7.70 (0.36)−5.56 (0.49)<0.00121–24−7.76 (0.37)−5.53 (0.50)<0.00125–28−8.01 (0.35)−6.29 (0.47)0.00329–32−8.20 (0.35)−6.59 (0.49)0.00733–36−8.00 (0.35)−6.61 (0.47)0.01537–40−8.12 (0.36)−6.79 (0.49)0.02141–44−8.36 (0.35)−6.69 (0.47)0.00345–48−8.39 (0.36)−6.85 (0.48)0.00749–52−8.26 (0.37)−6.93 (0.49)0.024 Open table in a new tab ResultsThe frequency of moderate-to-severe HFs was significantly reduced from baseline with DVS 100 mg at all time points up to week 52 (all comparisons P<0.001). The decreases in number of moderate-to-severe hot flushes with DVS were significantly greater than those observed in the placebo group at all time points up to week 52 (all comparisons P<0.05; Table). The frequency of moderate-to-severe HFs was significantly reduced from baseline with DVS 100 mg at all time points up to week 52 (all comparisons P<0.001). The decreases in number of moderate-to-severe hot flushes with DVS were significantly greater than those observed in the placebo group at all time points up to week 52 (all comparisons P<0.05; Table). ConclusionsIn this analysis, the significant decrease from baseline seen with DVS 100 mg was maintained and was significantly better than placebo for the full 52-week duration of the trial. In this analysis, the significant decrease from baseline seen with DVS 100 mg was maintained and was significantly better than placebo for the full 52-week duration of the trial.